NASDAQ:ANIK - Anika Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $37.47 -0.22 (-0.58 %) (As of 05/23/2019 01:14 AM ET)Previous Close$37.69Today's Range$37.33 - $38.1852-Week Range$28.54 - $46.43Volume83,260 shsAverage Volume177,232 shsMarket Capitalization$532.34 millionP/E Ratio20.36Dividend YieldN/ABeta1.41 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a resorbable knitted fabric mesh; HYALOSS MATRIX, HYAFF fibers used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment. The company's dermal products include wound care products that comprise HYALOMATRIX and HYALOFILL for the treatment of complex wounds, such as burns and ulcers, and for use in connection with the regeneration of skin; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise HYALOBARRIER, a post-operative adhesion barrier for use in the abdomino-pelvic area; MEROGEL, a woven fleece nasal packing; and MEROGEL INJECTABLE, a viscous hydrogel. The company also offers ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; and veterinary products, which include HYVISC, an injectable HA product for the treatment of joint dysfunction in horses. The company was founded in 1983 and is headquartered in Bedford, Massachusetts. Receive ANIK News and Ratings via Email Sign-up to receive the latest news and ratings for ANIK and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Supplies SectorMedical Current SymbolNASDAQ:ANIK Previous Symbol CUSIP03525510 CIK898437 Webhttp://www.anikatherapeutics.com/ Phone781-457-9000Debt Debt-to-Equity Ratio0.08 Current Ratio18.07 Quick Ratio16.12Price-To-Earnings Trailing P/E Ratio20.36 Forward P/E Ratio29.27 P/E Growth2.88 Sales & Book Value Annual Sales$105.56 million Price / Sales5.04 Cash Flow$2.3317 per share Price / Cash Flow16.07 Book Value$18.94 per share Price / Book1.98Profitability EPS (Most Recent Fiscal Year)$1.84 Net Income$18.72 million Net Margins27.44% Return on Equity11.57% Return on Assets10.68%Miscellaneous Employees133 Outstanding Shares14,207,000Market Cap$532.34 million Next Earnings Date7/24/2019 (Estimated) OptionableOptionable Anika Therapeutics (NASDAQ:ANIK) Frequently Asked Questions What is Anika Therapeutics' stock symbol? Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK." How were Anika Therapeutics' earnings last quarter? Anika Therapeutics Inc (NASDAQ:ANIK) posted its quarterly earnings results on Thursday, May, 2nd. The biotechnology company reported $0.31 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.10. The biotechnology company earned $24.72 million during the quarter, compared to the consensus estimate of $22.06 million. Anika Therapeutics had a net margin of 27.44% and a return on equity of 11.57%. The firm's revenue for the quarter was up 16.3% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.46) earnings per share. View Anika Therapeutics' Earnings History. When is Anika Therapeutics' next earnings date? Anika Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, July 24th 2019. View Earnings Estimates for Anika Therapeutics. What price target have analysts set for ANIK? 4 brokers have issued 1-year target prices for Anika Therapeutics' stock. Their predictions range from $35.00 to $44.00. On average, they expect Anika Therapeutics' share price to reach $38.6667 in the next twelve months. This suggests a possible upside of 3.2% from the stock's current price. View Analyst Price Targets for Anika Therapeutics. What is the consensus analysts' recommendation for Anika Therapeutics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Anika Therapeutics. Has Anika Therapeutics been receiving favorable news coverage? News coverage about ANIK stock has trended somewhat negative recently, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Anika Therapeutics earned a media sentiment score of -1.3 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future. Who are some of Anika Therapeutics' key competitors? Some companies that are related to Anika Therapeutics include Nevro (NVRO), Irhythm Technologies (IRTC), Atrion (ATRI), Shockwave Medical (SWAV), Mazor Robotics (MZOR), Silk Road Medical (SILK), Cardiovascular Systems (CSII), K2M Group (KTWO), AtriCure (ATRC), Cryolife (CRY), Orthofix Medical (OFIX), Luminex (LMNX), Tactile Systems Technology (TCMD), Axonics Modulation Technologies (AXNX) and Intersect ENT (XENT). What other stocks do shareholders of Anika Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Anika Therapeutics investors own include Celgene (CELG), Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Skyworks Solutions (SWKS), Exelixis (EXEL), GW Pharmaceuticals PLC- (GWPH), Mylan (MYL), Bausch Health Companies (BHC), Clovis Oncology (CLVS) and Allergan (AGN). Who are Anika Therapeutics' key executives? Anika Therapeutics' management team includes the folowing people: Mr. Joseph G. Darling, CEO, Pres & Director (Age 61)Ms. Sylvia Cheung, CFO, Treasurer & Sec. (Age 44)Dr. Edward S. Ahn, Chief Technology & Strategy Officer (Age 47)Mr. Thomas M. Finnerty, Chief HR Officer (Age 61)Mr. Alexei Goraltchouk, VP of Operations Who are Anika Therapeutics' major shareholders? Anika Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (14.97%), Kayne Anderson Rudnick Investment Management LLC (11.30%), Dimensional Fund Advisors LP (7.21%), Renaissance Technologies LLC (2.57%), BTIM Corp. (1.85%) and Wells Fargo & Company MN (1.54%). Company insiders that own Anika Therapeutics stock include Charles H Sherwood, Joseph G Darling, Raymond J Land and Richard Hague. View Institutional Ownership Trends for Anika Therapeutics. Which major investors are selling Anika Therapeutics stock? ANIK stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Assenagon Asset Management S.A., THB Asset Management, Oxford Asset Management LLP, Los Angeles Capital Management & Equity Research Inc., Parametric Portfolio Associates LLC, Gabelli Funds LLC and Citigroup Inc.. View Insider Buying and Selling for Anika Therapeutics. Which major investors are buying Anika Therapeutics stock? ANIK stock was acquired by a variety of institutional investors in the last quarter, including Kayne Anderson Rudnick Investment Management LLC, Renaissance Technologies LLC, Morgan Stanley, Hotchkis & Wiley Capital Management LLC, Hotchkis & Wiley Capital Management LLC, Bank of Montreal Can, Acadian Asset Management LLC and Dimensional Fund Advisors LP. View Insider Buying and Selling for Anika Therapeutics. How do I buy shares of Anika Therapeutics? Shares of ANIK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Anika Therapeutics' stock price today? One share of ANIK stock can currently be purchased for approximately $37.47. How big of a company is Anika Therapeutics? Anika Therapeutics has a market capitalization of $532.34 million and generates $105.56 million in revenue each year. The biotechnology company earns $18.72 million in net income (profit) each year or $1.84 on an earnings per share basis. Anika Therapeutics employs 133 workers across the globe. What is Anika Therapeutics' official website? The official website for Anika Therapeutics is http://www.anikatherapeutics.com/. How can I contact Anika Therapeutics? Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The biotechnology company can be reached via phone at 781-457-9000 or via email at [email protected] MarketBeat Community Rating for Anika Therapeutics (NASDAQ ANIK)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 216 (Vote Outperform)Underperform Votes: 202 (Vote Underperform)Total Votes: 418MarketBeat's community ratings are surveys of what our community members think about Anika Therapeutics and other stocks. Vote "Outperform" if you believe ANIK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANIK will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/23/2019 by MarketBeat.com StaffFeatured Article: What is a good rate of return for a mutual fund? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.